Sepsis-Associated Encephalopathy
Recent clinical, regulatory, research and industry developments relating to this disease.
Blood-Brain Barrier Disruption by Lipopolysaccharide and Sepsis-Associated Encephalopathy.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Sepsis-Associated Encephalopathy4
- Cognitive Dysfunction2
- Hippocampus2
- Neuronal Plasticity2
- Sepsis2
- Brain Diseases1
- Brain-Derived Neurotrophic Factor1
- Cytoskeletal Proteins1
Leading journals5
- CNS neuroscience & therapeutics1
- Critical care medicine1
- Current neuropharmacology1
- Frontiers in cellular and infection microbiology1
- Molecular therapy : the journal of the American Society of Gene Therapy1
Leading researchers8
- Battaglini D1
- Bauer M1
- Blaess M1
- Chai X1
- Cho SM1
- Chung HY1
- Claus RA1
- Diao YG1
Affiliations (unnormalised)6
- Air Force Medical Center1
- Brigham and Women's Hospital1
- Center for Sepsis Control and Care1
- Department of Clinical Medicine1
- General Hospital of Northern Theater Command1
- Griffith University School of Medicine1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Sepsis-associated encephalopathy is an acute neurological dysfunction that occurs during severe sepsis without direct infection of the brain. It is characterized by systemic inflammation and disruption of the blood-brain barrier. The literature also describes it as a form of cognitive and psychological impairment that can occur without central nervous system infection or structural brain injury.
The grounding supports sepsis as the underlying condition and indicates that lipopolysaccharide from Gram-negative bacteria can contribute by damaging the blood-brain barrier. No additional specific causes are supported beyond severe sepsis and related inflammatory injury.
The central mechanism described is blood-brain barrier perturbation, which allows inflammatory factors and neurotoxins to enter the brain and damage neural tissue. This can activate brain immune cells and amplify inflammatory responses, creating a vicious cycle of further barrier injury. The literature also points to glial cell activation and altered synaptic plasticity as important parts of the pathological process.
Severe sepsis is the main supported risk context for this syndrome. The supplied grounding does not support additional specific risk factors.
The supplied grounding supports treatment only at a broad modality level and does not provide a specific standard regimen. It indicates that the literature covers therapy, but no particular drug class or intervention is explicitly supported in the provided material. Neurologic monitoring is discussed in the literature, but not as a treatment standard.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Acute neurological dysfunction during severe SEPSIS in the absence of direct brain infection characterized by systemic inflammation and BLOOD BRAIN BARRIER perturbation.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.